Korea Pharmacy Co. Ltd. (032300) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of Korea Pharmacy Co. Ltd. stock KRW 4,188, price KRW 8,170, upside -48.7%, quality 46 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value 30%+ above price?No
Quality 50+?No
In an uptrend?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 28, 2026.
How to read this chart
60‑month range 6,800 KRW – 83,237 KRW · fair‑value band 3,257 KRW – 5,181 KRW · the 8,170 KRW price screens above the 4,188 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 28, 2026.
Follow Korea Pharmacy Co. in your weekly email
Every Wednesday you see whether Korea Pharmacy Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
KOREA PHARMA Co., Ltd. . produces pharmaceutical drugs.
Show moreShow less
The company offers amino acid, antibiotic, antidotal, antiepileptic, antihistamine, anti-inflammatory, antimicrobial, antiplatelet, circulatory system, CNS, dermatological, endocrine, gastrointestinal, hepatic, hormonal, respiratory, sympathomimetic, skeltal muscle relaxants, and specialty drugs, as well as multivitamins, and vitamin B1, etc.
KOREA PHARMA Co., Ltd. was founded in 1974 and is based in Seoul, South Korea.
Stock analysis
Korea Pharmacy Co. Ltd. (032300) currently trades at 8,170 KRW, while our model-based Fair Value estimate is 4,188 KRW, 48.7% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 4,188 KRW per share, and 0 of the 10 models we run sit above the 8,170 KRW price.
Bear case: the Asset-Based group reads lowest at 597.36 KRW, and 10 of the 10 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 3,257 KRW (bear) to 5,181 KRW (bull), the price of 8,170 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 46/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Korea Pharmacy Co. Ltd. reported revenue of 87.6B KRW in FY2025 versus 79.6B KRW in FY2021, a compound +2.4%/yr. Reported net income was −2.6B KRW in FY2025.
Key figures
Market cap 89.1B KRW (≈ $66.7M) Micro · P/S ratio 0.95 · EPS (TTM) −70.92 KRW · Dividend yield 0.6% · Net margin −0.8% · Return on equity −1.1% · Return on assets (EBIT) 3.6% · Operating margin 8.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 20 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 20% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −24% fair-value upside, at −49%, 032300 screens richer than that median.
Fair Value models
Bear3,257 KRWFair Value 4,188 KRWBull5,181 KRW
Price 8,170 KRW · Upside -48.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.39/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+7.8%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.1%
Start year 2020 (pandemic)
Revenue growth 7 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.4%
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
6.4% (2020) → −1.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+43.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about +40.4% a year for the price.
Compare Korea Pharmacy Co. Ltd. with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 579 stocks
Beats the industry median on 3/12 measures
Overall it trails its industry peers.
Valuation
Quality Score46 · Below median
Fair Value upside−48.7% · Below median
Profitability
Return on assets−2.1% · Bottom 25%
Net margin (12 months)−0.8% · Below median
Operating margin (12 months)8.4% · Below median
Growth and dividend
Revenue growth (quarter YoY)10.8% · Above median
Dividend yield (12 months)0.6% · Bottom 25%
Balance sheet
Debt / equity0.27× · Highest 25%
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
P/B1.30× · Cheaper than median
P/S (12 months)0.95× · Cheapest 25%
Price / free cash flow65.8× · Priciest 25%
EV/EBITDA16.9× · Pricier than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 20
FUTURE (revenue growth)54· sector 26
PAST (return on equity)0· sector 28
HEALTH (low debt)87· sector 96
DIVIDEND (yield)12· sector 33
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Korea Pharmacy Co. Ltd. (032300) overvalued or undervalued?
As of Oct 28, 2026, our model estimates a fair value of 4,188 KRW versus a price of 8,170 KRW, about −49% upside (overvalued).
What is the fair value of 032300?
Our model-based fair value for Korea Pharmacy Co. Ltd. is 4,188 KRW (as of Oct 28, 2026), built from audited fundamentals. The current price: 8,170 KRW.
What is the quality score of 032300?
Korea Pharmacy Co. Ltd. has a Quality Score of 46/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Korea Pharmacy Co. Ltd. (032300)?
Our model-based price target is the fair value of 4,188 KRW (as of Oct 28, 2026) from 10 valuation models. Cautious scenario 3,257 KRW, optimistic scenario 5,181 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Korea Pharmacy Co. Ltd. stock forecast for 2026?
Our models put fair value at 4,188 KRW, about −49% upside versus a price of 8,170 KRW (overvalued). Cautious scenario 3,257 KRW, optimistic scenario 5,181 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Korea Pharmacy Co. Ltd. (032300)?
Korea Pharmacy Co. Ltd. reported trailing-twelve-month revenue of about 93.9B KRW (latest available figure, as of Oct 28, 2026).
Does Korea Pharmacy Co. Ltd. pay a dividend?
Korea Pharmacy Co. Ltd. currently shows a dividend yield of 0.61% relative to its recent price (as of Oct 28, 2026).
What growth is priced into Korea Pharmacy Co. Ltd. (032300)?
For today's price to be fair in a discounted-cash-flow model, Korea Pharmacy Co. Ltd. would have to grow free cash flow by +43.3 % per year for five years (discount rate 12.1 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +4.1 % per year. As of Oct 28, 2026.
What discount rate (WACC) does the fair value of 032300 use?
Our models discount Korea Pharmacy Co. Ltd. at 12.1 %: a base by market capitalisation (micro), damped by beta 0.67, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Korea Pharmacy Co. Ltd. that is +43.3 % per year a year over ten years, using the same discount rate (12.1 %) and the same formula as our fair value.
How much growth has Korea Pharmacy Co. Ltd. (032300) delivered so far?
Over the past 5 years revenue at Korea Pharmacy Co. Ltd. grew +4.1 % a year. The price currently implies +43.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Korea Pharmacy Co. Ltd. (032300) growing?
The median revenue growth in the sector is +13.0 % a year. That is the yardstick for the growth priced into Korea Pharmacy Co. Ltd. (+43.3 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Korea Pharmacy Co. Ltd. (032300)?
The free-cash-flow yield on the price is 1.52 %: that much free cash flow Korea Pharmacy Co. Ltd. produces per unit of market value. When it exceeds the discount rate of our models (12.1 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Korea Pharmacy Co. Ltd. (032300)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Korea Pharmacy Co. Ltd. it is 4,188 KRW per share (as of Oct 28, 2026), against a price of 8,170 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Korea Pharmacy Co. Ltd. stock overvalued or undervalued in 2026?
As of Oct 28, 2026, 032300 trades above its calculated fair value: price 8,170 KRW, fair value 4,188 KRW, a gap of about −49% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 032300?
No. The price is what the market pays today (8,170 KRW); the fair value is what the company's own numbers justify (4,188 KRW). For Korea Pharmacy Co. Ltd. the two are 3,982 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Korea Pharmacy Co. Ltd. worth?
The market values Korea Pharmacy Co. Ltd. at about 89.1B KRW (market capitalisation, as of Oct 28, 2026). Per share that is 8,170 KRW; our models calculate a fair value of 4,188 KRW per share.
What do the bullish and bearish scenarios say about 032300?
Our models span a range for Korea Pharmacy Co. Ltd.: cautious scenario 3,257 KRW, base 4,188 KRW, optimistic 5,181 KRW per share (as of Oct 28, 2026, price 8,170 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Korea Pharmacy Co. Ltd. (032300)?
Balance-sheet figures for Korea Pharmacy Co. Ltd. (as of Oct 28, 2026): return on equity −1.1%, debt of 0.27 per unit of equity. They feed the Quality Score of 46/100, which measures business quality independently of the share price.
How far is 032300 from its 52-week high?
Korea Pharmacy Co. Ltd. trades at 8,170 KRW, about 42% below its 52-week high of 14,090 KRW and 20% above the low of 6,800 KRW (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 4,188 KRW is for.
Which stocks are comparable to Korea Pharmacy Co. Ltd.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Korea Pharmacy Co. Ltd. stock attractive at the current price?
The data as of Oct 28, 2026: price 8,170 KRW, calculated fair value 4,188 KRW (−49%), Quality Score 46/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 032300 calculated?
We run Korea Pharmacy Co. Ltd. through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 4,188 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Korea Pharmacy Co. Ltd. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Korea Pharmacy Co. Ltd. (032300)?
The closing price on Oct 28, 2026 was 8,170 KRW. Our model-based fair value is 4,188 KRW, about −49% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Korea Pharmacy Co. Ltd. right now?
The price sits above even our optimistic bull case (5,181 KRW). The favourable scenario is already priced in. Solid but not exceptional quality (46/100) and above fair value, neither a clear bargain nor a standout compounder.
Key figures of Korea Pharmacy Co. Ltd.
How large is the market capitalisation of Korea Pharmacy Co. Ltd. (032300)?
The market capitalisation of Korea Pharmacy Co. Ltd. is 89.1B KRW (≈ $66.7M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Korea Pharmacy Co. Ltd. (032300)?
The price-to-sales ratio of Korea Pharmacy Co. Ltd. is 0.95 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Korea Pharmacy Co. Ltd. (032300)?
Earnings per share at Korea Pharmacy Co. Ltd. are −70.92 KRW. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Korea Pharmacy Co. Ltd. (032300)?
The dividend yield of Korea Pharmacy Co. Ltd. is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Korea Pharmacy Co. Ltd. (032300)?
The net margin of Korea Pharmacy Co. Ltd. is −0.8% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Korea Pharmacy Co. Ltd. (032300)?
The return on equity (ROE) of Korea Pharmacy Co. Ltd. is −1.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Korea Pharmacy Co. Ltd. (032300)?
On an EBIT basis the return on assets of Korea Pharmacy Co. Ltd. is 3.6% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Korea Pharmacy Co. Ltd. (032300)?
The operating margin of Korea Pharmacy Co. Ltd. is 8.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Korea Pharmacy Co. Ltd. (032300)?
Revenue at Korea Pharmacy Co. Ltd. is growing +10.8% versus a year earlier (3y avg +2.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Korea Pharmacy Co. Ltd. (032300)?
Earnings per share at Korea Pharmacy Co. Ltd. are growing +33.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Korea Pharmacy Co. Ltd. (032300) carry?
The net debt of Korea Pharmacy Co. Ltd. is 10.1B KRW (fiscal year 2025, ≈ 7.4 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Korea Pharmacy Co. Ltd. in the live analysis
One click puts Korea Pharmacy Co. Ltd. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Some data
Oct 28, 2026